Cempra Details Launch Plans For Solithromycin
This article was originally published in The Pink Sheet Daily
Executive Summary
Expecting approval for CABP before the end of 2016, Cempra says solithromycin will offer a significant treatment-resistance edge over the earlier macrolide antibiotic azithromycin.